An eventful year — including panel meetings, approvals and a refusal to file a new drug application — has sharpened the focus around the FDA's requirements for accelerated approval of anticancer drugs.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Mullard, A. Accelerated approval dust begins to settle. Nat Rev Drug Discov 10, 797–798 (2011). https://doi.org/10.1038/nrd3580
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd3580
This article is cited by
-
Upcoming market catalysts in Q1 2012
Nature Reviews Drug Discovery (2012)
